BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Colin Bristow does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 ALXOAlx Oncology Holdings | Buy | $1.00 | May 2025 | +300.0% | Hit |
 ABOSAcumen Pharmaceuticals Inc | Buy | $4.00 | Mar 2025 | +98.8% | Miss |
| ALXOAlx Oncology Holdings | Buy | $2.20 | Jan 2025 | −9.9% | Hit |
| ALXOAlx Oncology Holdings | Buy | $4.00 | Aug 2024 | −52.1% | Miss |
| ABOSAcumen Pharmaceuticals Inc | Buy | $6.00 | Aug 2024 | −35.4% | Miss |
 PROKProKidney Corp. | Buy | $18.00 | Oct 2022 | −83.9% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.